Action 8: Support and fund clinical and implementation research to inform development and approval as well as use of paediatric formulations included in the PADO list.

Action 9: Only fund the procurement of drugs and formulations recommended by WHO that are included in the Optimal Formulary.

Action 21: Provide funding to support actions required for quickly introducing and scale-up new, optimal paediatric formulations.

46. Contribute to the funding of the secretariat of the Global Accelerator and its activities as outlined in the product portfolio of the GAP-f business plan